{"nctId":"NCT00907777","briefTitle":"Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™","startDateStruct":{"date":"2009-06-23","type":"ACTUAL"},"conditions":["Infections, Streptococcal","Streptococcus Pneumoniae"],"count":52,"armGroups":[{"label":"Pn Group","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK 1024850A"]},{"label":"Prev Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)"]}],"interventions":[{"name":"Pneumococcal conjugate vaccine GSK 1024850A","otherNames":[]},{"name":"Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female between, and including, 46-50 months of age at the time of vaccination.\n* Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.\n* Subjects who previously participated in study NCT00333450 in centres with more than 2 subjects and received a booster dose of Pneumovax 23™.\n* Written informed consent obtained from both parents/guardians of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the vaccination, or planned use during the study period.\n* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccination.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before study vaccination and during the entire study period.\n* Administration of any pneumococcal vaccine since the end of study NCT00333450.\n* Administration of immunoglobulins and/or any blood products less than 3 months prior to the vaccination or planned use during the study period.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical\n* History of any neurologic disorders or seizures\n* Anaphylactic reaction following previous administration of the vaccine or history of reactions or allergic disease likely to be exacerbated by any component of the vaccine.\n* History of hypotonic-hyporesponsive episode after any previous vaccination.\n* Major congenital defects or serious chronic illness.\n* History of invasive pneumococcal diseases.\n* Acute disease at the time of vaccination\n* Rectal temperature \\>= 38.0°C or oral/axillary/tympanic temperature \\>= 37.5°C. A temperature greater than or equal to these cut-offs warrants deferral of the vaccination pending recovery of the subject.","healthyVolunteers":true,"sex":"ALL","minimumAge":"46 Months","maximumAge":"50 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Vaccine Pneumococcal Serotype Antibody Concentrations","description":"The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":null},{"groupId":"OG001","value":"1.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":null},{"groupId":"OG001","value":"0.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"6.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"1.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":null},{"groupId":"OG001","value":"0.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.46","spread":null},{"groupId":"OG001","value":"1.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":null},{"groupId":"OG001","value":"0.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":null},{"groupId":"OG001","value":"2.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":null},{"groupId":"OG001","value":"0.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.88","spread":null},{"groupId":"OG001","value":"2.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.82","spread":null},{"groupId":"OG001","value":"9.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":null},{"groupId":"OG001","value":"0.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.23","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":null},{"groupId":"OG001","value":"2.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.68","spread":null},{"groupId":"OG001","value":"15.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.82","spread":null},{"groupId":"OG001","value":"1.27","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes","description":"The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"49.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":null},{"groupId":"OG001","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4814","spread":null},{"groupId":"OG001","value":"4380.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188.2","spread":null},{"groupId":"OG001","value":"66.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6734.3","spread":null},{"groupId":"OG001","value":"1424.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1202.9","spread":null},{"groupId":"OG001","value":"1498.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1304.2","spread":null},{"groupId":"OG001","value":"4657.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"612.9","spread":null},{"groupId":"OG001","value":"442","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5829.4","spread":null},{"groupId":"OG001","value":"2843.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149.7","spread":null},{"groupId":"OG001","value":"330","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5400.8","spread":null},{"groupId":"OG001","value":"2812.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"23.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1615.2","spread":null},{"groupId":"OG001","value":"2806.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":null},{"groupId":"OG001","value":"35.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241.6","spread":null},{"groupId":"OG001","value":"837.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1430.2","spread":null},{"groupId":"OG001","value":"1383.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23977.2","spread":null},{"groupId":"OG001","value":"4865.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Cross-reactive Pneumococcal Serotype Antibody Concentrations","description":"The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null},{"groupId":"OG001","value":"0.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":null},{"groupId":"OG001","value":"0.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":null},{"groupId":"OG001","value":"0.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"1.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes","description":"The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106.9","spread":null},{"groupId":"OG001","value":"117.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2320.4","spread":null},{"groupId":"OG001","value":"966.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.3","spread":null},{"groupId":"OG001","value":"153.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-protein D Antibody Concentrations","description":"The anti-protein D antibody cut-off value (greater than or equal to ≥100 EL.U/mL) was assessed by Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.1","spread":null},{"groupId":"OG001","value":"173.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null},{"groupId":"OG001","value":"1135.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms","description":"Solicited local symptoms assessed include pain, redness, and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger (\\>) 30 millimeters (mm). \"Any\" is defined as incidence of the specified symptom regardless of intensity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (\\>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal everyday activities. Grade 3 loss of appetite was defined as the subject not eating at all. \"Any\" is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Unsolicited Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. \"Any\" is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Pain","Redness","Swelling","Drowsiness","Loss of appetite"]}}}